Search details
1.
DrugMap: A quantitative pan-cancer analysis of cysteine ligandability.
Cell
; 187(10): 2536-2556.e30, 2024 May 09.
Article
in English
| MEDLINE | ID: mdl-38653237
2.
Precision Oncology Comes of Age: Designing Best-in-Class Small Molecules by Integrating Two Decades of Advances in Chemistry, Target Biology, and Data Science.
Cancer Discov
; 13(10): 2131-2149, 2023 10 05.
Article
in English
| MEDLINE | ID: mdl-37712571
3.
STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3Kα-Mutant Xenografts.
Cancer Discov
; 13(11): 2432-2447, 2023 11 01.
Article
in English
| MEDLINE | ID: mdl-37623743
4.
DrugMap: A quantitative pan-cancer analysis of cysteine ligandability.
bioRxiv
; 2023 Oct 23.
Article
in English
| MEDLINE | ID: mdl-37961514
5.
Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer.
J Med Chem
; 65(14): 9662-9677, 2022 07 28.
Article
in English
| MEDLINE | ID: mdl-35838760
6.
Identification of 2-oxatriazines as highly potent pan-PI3K/mTOR dual inhibitors.
Bioorg Med Chem Lett
; 21(16): 4773-8, 2011 Aug 15.
Article
in English
| MEDLINE | ID: mdl-21763134
7.
Discovery of 3,6-dihydro-2H-pyran as a morpholine replacement in 6-aryl-1H-pyrazolo[3,4-d]pyrimidines and 2-arylthieno[3,2-d]pyrimidines: ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR).
Bioorg Med Chem Lett
; 20(2): 640-3, 2010 Jan 15.
Article
in English
| MEDLINE | ID: mdl-19963384
8.
4-Substituted-7-azaindoles bearing a ureidobenzofuranone moiety as potent and selective, ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR).
Bioorg Med Chem Lett
; 20(7): 2259-63, 2010 Apr 01.
Article
in English
| MEDLINE | ID: mdl-20188551
9.
Novel benzofuran-3-one indole inhibitors of PI3 kinase-alpha and the mammalian target of rapamycin: hit to lead studies.
Bioorg Med Chem Lett
; 20(8): 2586-90, 2010 Apr 15.
Article
in English
| MEDLINE | ID: mdl-20303263
10.
5-ureidobenzofuranone indoles as potent and efficacious inhibitors of PI3 kinase-alpha and mTOR for the treatment of breast cancer.
Bioorg Med Chem Lett
; 20(12): 3526-9, 2010 Jun 15.
Article
in English
| MEDLINE | ID: mdl-20483602
11.
Novel purine and pyrazolo[3,4-d]pyrimidine inhibitors of PI3 kinase-alpha: Hit to lead studies.
Bioorg Med Chem Lett
; 20(2): 636-9, 2010 Jan 15.
Article
in English
| MEDLINE | ID: mdl-19969455
12.
Discovery and optimization of 2-(4-substituted-pyrrolo[2,3-b]pyridin-3-yl)methylene-4-hydroxybenzofuran-3(2H)-ones as potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR).
Bioorg Med Chem Lett
; 20(7): 2321-5, 2010 Apr 01.
Article
in English
| MEDLINE | ID: mdl-20188552
13.
Novel imidazolopyrimidines as dual PI3-Kinase/mTOR inhibitors.
Bioorg Med Chem Lett
; 20(2): 653-6, 2010 Jan 15.
Article
in English
| MEDLINE | ID: mdl-19954970
14.
Chemical space sampling by different scoring functions and crystal structures.
J Comput Aided Mol Des
; 24(5): 433-47, 2010 May.
Article
in English
| MEDLINE | ID: mdl-20401681
15.
Biased retrieval of chemical series in receptor-based virtual screening.
J Comput Aided Mol Des
; 24(12): 1053-62, 2010 Dec.
Article
in English
| MEDLINE | ID: mdl-21053053
16.
5-Vinyl-3-pyridinecarbonitrile inhibitors of PKCtheta: optimization of enzymatic and functional activity.
Bioorg Med Chem
; 17(23): 7933-48, 2009 Dec 01.
Article
in English
| MEDLINE | ID: mdl-19884013
17.
Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.
Cancer Discov
; 9(12): 1686-1695, 2019 12.
Article
in English
| MEDLINE | ID: mdl-31575540
18.
Targeting kinases with precision.
Mol Cell Oncol
; 5(3): e1435183, 2018.
Article
in English
| MEDLINE | ID: mdl-30250891
19.
A precision therapy against cancers driven by KIT/PDGFRA mutations.
Sci Transl Med
; 9(414)2017 Nov 01.
Article
in English
| MEDLINE | ID: mdl-29093181
20.
Large scale meta-analysis of fragment-based screening campaigns: privileged fragments and complementary technologies.
J Biomol Screen
; 20(5): 588-96, 2015 Jun.
Article
in English
| MEDLINE | ID: mdl-25550355